oncology-therpeutics-2017-scientifictracks

23 / 28

Page 45
Notes:
allied
academies
J Med Oncl Ther 2017 Volume 2 | Issue 3
International Conference on
Oncology and Cancer Therapeutics
October 30- November 01, 2017 | Chicago, USA
Targeting escape signaling in resistant non-Hodgkin’s lymphoma
Lalit Sehgal
The University of Texas MD Anderson Cancer Center, USA
Diffuse large B cell lymphoma (DLBCL) is the most
common subtype of non-Hodgkin lymphoma (NHL) with
1400 cases diagnosed yearly in the USA. While some patient
can be cured for like, approximately 30% of these patients
have lymphoma that comes back despite therapy and will
die prematurely. In recent years advances in treatment have
shown Ibrutinib blocks a driver of cancer termed BTK. While
ibrutinib is initially effective, most individuals with different
types of lymphomas develop resistance to and have a short
survival. With this growing problem on potentially curable
lymphoma, we plan to learn how ibrutinib stops working
and overcome this problem with mechanistically derived
new treatments for DLBCL, which will apply to many blood
cancers. There are two major problems that stand in the
way of identifying curative therapy. One is an incomplete
understanding of drugs blocking the driver Bruton tyrosine
kinase (BTK) which loses its effectiveness and allows
regrowth of DLBCL. A second problem is suppressed immune
cells which would normally recognize and eliminate DLBCL,
but in relapsed DLBCL fail to eliminate DLBCL. Said another
way, the immune cells have the brakes applied and are not
free to eliminate DLBCL cells. We have made progress to
show possible ways to understand how ibrutinib drug loses
its effectiveness. The information contained in this e-mail
message may be privileged, confidential, and/or protected
from disclosure. This e-mail message may contain protected
health information (PHI); dissemination of PHI should
comply with applicable federal and state laws. If you are not
the intended recipient, or an authorized representative of
the intended recipient, any further review, disclosure, use,
dissemination, distribution, or copying of this message or
any attachment (or the information contained therein) is
strictly prohibited. If you think that you have received this
e-mail message in error, please notify the sender by return
e-mail and delete all references to it and its contents from
your systems.
Speaker Biography
Lalit Sehgal has research interests focused on the communication between lymphoma
cells and stromal cells. His recent finding revealed that communication between the
tumor and stroma could modulate the expression of key oncogene, which can be
further targeted for effective therapy in MCL relapse. The findings have forwarded the
hematology field by exploring new targets for therapy.
e: